# Pfizer Inc.  Share Price Target ‘$29.15’, now 5.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/pfizer-inc.share-price-target-29.15-now-5.2-upside-potential/4121163969
- Published: 2024-07-05T16:06:18+01:00
- Author: Charlotte Edwards

**Pfizer Inc.** with ticker code (PFE) have now 22 analysts in total covering the
stock. The consensus rating is pointing to ‘buy’. The range between the high target
price and low target price is between $41.69 and $25.02 and has a mean share price
target at $29.15. (at the time of writing). Now with the previous closing price 
of $27.70 this is indicating there is a potential upside of 5.2%. There is a 50 
day moving average of $27.92 and the 200 day moving average is $28.72. The company
has a market cap of 157.59B. The current share price for the company is: $27.81 
USD

 The potential market cap would be $165,837,049,900 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $9.72 and
a 0.93% return on assets.

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged
in the discovery, development, manufacture, marketing, sale and distribution of 
biopharmaceutical products around the world. The Company operates through two segments:
Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business.
PC1 is its global contract development and manufacturing organization and supplier
of specialty active pharmaceutical ingredients. The Company’s primary care products
include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, 
Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty
care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra,
Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin,
and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products
include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Share on: